Grisanti Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Grisanti Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,000	Closed	-$84K	–	78
2017 Q4	$84K	Buy	+6,000	New	+$81.1K	0.03%	54
2017 Q3	–	Sell	-20,800	Closed	-$351K	–	71
2017 Q2	$351K	Buy	+20,800	New	+$317K	0.15%	45

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Grisanti Capital Management's MNTA Position: Q1 2018 in Review

Grisanti Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2018, closing a stake of 6,000 shares — an estimated $84K sold.

Grisanti Capital Management first reported a position in MNTA in Q2 2017 and held it in 2 quarters. The position peaked at $351K in Q2 2017. 163 funds tracked by Wall St. Rank hold MNTA as of Q1 2018.

Grisanti Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Grisanti Capital Management sold 6,000 Momenta Pharmaceuticals, Inc. shares in Q1 2018, an estimated $84K.
Grisanti Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
Grisanti Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $351K in Q2 2017.
163 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2018.

Based on Grisanti Capital Management's 13F filing for Q1 2018, filed 2 May 2018.